LIDDS has employed Charlotta Gauffin as Head of Clinical Development. Charlotta will join the company in March 2019 and be responsible for the Phase IIb clinical study for Liproca® Depot and the Phase I study to assess NanoZolid® in combination with docetaxel.
Charlotta Gauffin has extensive experience in clinical trials and project management from positions at Quintiles, Q-Med and Galderma. She holds a PhD in Organic Chemistry from the University of Uppsala. Charlotta will become a member of the LIDDS management team.
-LIDDS is pleased to welcome Charlotta to the management team. She has a solid background and broad experience in clinical trial management which will be important for finalizing the LPC-004 study and managing the NZ-DTX Phase I study. Charlotta will become a full-time employee and replace Carl-Gustaf Gölander who has made a significant contribution at LIDDS as Study Director and Clinical Program Leader, working part-time since 2015, says Monica Wallter, CEO.
-I look forward to contributing to LIDDS clinical development and to join the management team. The NanoZolid® technology is very exciting and creates many opportunities for both patients and the pharmaceutical industry, says Charlotta Gauffin.
Charlotta Gauffin is leaving a position as Senior Clinical Project Manager at Galderma.
For more information, please contact:
Monica Wallter, CEO LIDDS, +46 (0)737 07 09 22, firstname.lastname@example.org
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is superior to any drug delivery technology in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in preclinical phase for cytostatics and immunoactive agents. LIDDS shares (LIDDS) are listed on Nasdaq First North. Redeye AB, Certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com